Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis
Purpose Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its acti...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2019-01, Vol.83 (1), p.71-79 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 79 |
|---|---|
| container_issue | 1 |
| container_start_page | 71 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 83 |
| creator | Bai, Yu Wu, Hai-wei Zhang, Yan-hua |
| description | Purpose
Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.
Methods
The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.
Results
In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each
CYP2D6
*
10
genotype group (
p
|
| doi_str_mv | 10.1007/s00280-018-3703-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2124646215</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2124646215</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-a50b46e78a51a9f9ff9e1bdd9834efb07e58a6285bed8bd0f5c3517222afd883</originalsourceid><addsrcrecordid>eNp1kE2P1DAMhiMEYoeFH8AFReIccL7alNtqWD6kleCwF06R2zpMlmlTkgww_56OZoETJ0v268fWw9hzCa8kQPu6ACgHAqQTugUt3AO2kUYrAc7oh2wD2hhhWzAX7EkpdwBgpNaP2YUGbVtjug37cR0CDbXwFPj2y2f1tpHAl7Q_Tikvu1gmnmZecUq_YqCZLzvMEw7pW5ypxqHwuPawRppXxM9Yd7zPhKXyAeeB8ml8VSK-4cgnqihwxv2xxPKUPQq4L_Tsvl6y23fXt9sP4ubT-4_bqxsx6FZVgRZ601Dr0ErsQhdCR7Ifx85pQ6GHlqzDRjnb0-j6EYIdtJWtUgrD6Jy-ZC_P2CWn7wcq1d-lQ15_KF5JZRrTKGnXlDynhpxKyRT8kuOE-egl-JNofxbtV9H-JNqfyC_uyYd-ovHvxh-za0CdA2UdzV8p_zv9f-pvhtuJTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2124646215</pqid></control><display><type>article</type><title>Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis</title><source>SpringerLink Journals</source><creator>Bai, Yu ; Wu, Hai-wei ; Zhang, Yan-hua</creator><creatorcontrib>Bai, Yu ; Wu, Hai-wei ; Zhang, Yan-hua</creatorcontrib><description>Purpose
Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.
Methods
The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.
Results
In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each
CYP2D6
*
10
genotype group (
p
< 0.05). The CC genotype was associated with higher concentrations of 4-OH-TAM than the CT/TT genotype (
p
< 0.05). However, there were no statistically significant between-group differences in serum concentrations of TAM (
p
> 0.05). Publication bias and sensitivity analyses confirmed that the meta-analysis results were stable and reliable.
Conclusions
CYP2D6
*
10
polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-018-3703-8</identifier><identifier>PMID: 30357449</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Bias ; Biopsy ; Breast cancer ; Cancer ; Cancer Research ; Confidence intervals ; Correlation analysis ; CYP2D6 protein ; Cytochrome ; Cytochrome P450 ; Cytochromes P450 ; Gene polymorphism ; Genotype & phenotype ; Medicine ; Medicine & Public Health ; Meta-analysis ; Metabolites ; Oncology ; Original Article ; Patients ; Pharmacokinetics ; Pharmacology ; Pharmacology/Toxicology ; Polymorphism ; Sensitivity ; Sensitivity analysis ; Statistical analysis ; Tamoxifen</subject><ispartof>Cancer chemotherapy and pharmacology, 2019-01, Vol.83 (1), p.71-79</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-a50b46e78a51a9f9ff9e1bdd9834efb07e58a6285bed8bd0f5c3517222afd883</citedby><cites>FETCH-LOGICAL-c372t-a50b46e78a51a9f9ff9e1bdd9834efb07e58a6285bed8bd0f5c3517222afd883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-018-3703-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-018-3703-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30357449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Yu</creatorcontrib><creatorcontrib>Wu, Hai-wei</creatorcontrib><creatorcontrib>Zhang, Yan-hua</creatorcontrib><title>Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.
Methods
The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.
Results
In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each
CYP2D6
*
10
genotype group (
p
< 0.05). The CC genotype was associated with higher concentrations of 4-OH-TAM than the CT/TT genotype (
p
< 0.05). However, there were no statistically significant between-group differences in serum concentrations of TAM (
p
> 0.05). Publication bias and sensitivity analyses confirmed that the meta-analysis results were stable and reliable.
Conclusions
CYP2D6
*
10
polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.</description><subject>Bias</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Confidence intervals</subject><subject>Correlation analysis</subject><subject>CYP2D6 protein</subject><subject>Cytochrome</subject><subject>Cytochrome P450</subject><subject>Cytochromes P450</subject><subject>Gene polymorphism</subject><subject>Genotype & phenotype</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Metabolites</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Polymorphism</subject><subject>Sensitivity</subject><subject>Sensitivity analysis</subject><subject>Statistical analysis</subject><subject>Tamoxifen</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kE2P1DAMhiMEYoeFH8AFReIccL7alNtqWD6kleCwF06R2zpMlmlTkgww_56OZoETJ0v268fWw9hzCa8kQPu6ACgHAqQTugUt3AO2kUYrAc7oh2wD2hhhWzAX7EkpdwBgpNaP2YUGbVtjug37cR0CDbXwFPj2y2f1tpHAl7Q_Tikvu1gmnmZecUq_YqCZLzvMEw7pW5ypxqHwuPawRppXxM9Yd7zPhKXyAeeB8ml8VSK-4cgnqihwxv2xxPKUPQq4L_Tsvl6y23fXt9sP4ubT-4_bqxsx6FZVgRZ601Dr0ErsQhdCR7Ifx85pQ6GHlqzDRjnb0-j6EYIdtJWtUgrD6Jy-ZC_P2CWn7wcq1d-lQ15_KF5JZRrTKGnXlDynhpxKyRT8kuOE-egl-JNofxbtV9H-JNqfyC_uyYd-ovHvxh-za0CdA2UdzV8p_zv9f-pvhtuJTA</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Bai, Yu</creator><creator>Wu, Hai-wei</creator><creator>Zhang, Yan-hua</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20190101</creationdate><title>Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis</title><author>Bai, Yu ; Wu, Hai-wei ; Zhang, Yan-hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-a50b46e78a51a9f9ff9e1bdd9834efb07e58a6285bed8bd0f5c3517222afd883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bias</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Confidence intervals</topic><topic>Correlation analysis</topic><topic>CYP2D6 protein</topic><topic>Cytochrome</topic><topic>Cytochrome P450</topic><topic>Cytochromes P450</topic><topic>Gene polymorphism</topic><topic>Genotype & phenotype</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Metabolites</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Polymorphism</topic><topic>Sensitivity</topic><topic>Sensitivity analysis</topic><topic>Statistical analysis</topic><topic>Tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Yu</creatorcontrib><creatorcontrib>Wu, Hai-wei</creatorcontrib><creatorcontrib>Zhang, Yan-hua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Yu</au><au>Wu, Hai-wei</au><au>Zhang, Yan-hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>83</volume><issue>1</issue><spage>71</spage><epage>79</epage><pages>71-79</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Purpose
Insufficient serum metabolite concentrations of tamoxifen can compromise treatment efficacy in patients with breast cancer. The purpose of this meta-analysis was to explore correlations between cytochrome P450 (CYP) 2D6*10 gene polymorphisms and serum concentrations of tamoxifen and its active metabolites in patients with breast cancer in Asia.
Methods
The study included a systematic literature search for cohort studies published before March 2018 in English databases (PubMed, Embase, Cochrane Library, and Web of Science) and Chinese databases (Chinese National Knowledge Infrastructure and Wan Fang database). The meta-analysis was performed using RevMan 5.3 software. Pooled means and standard deviations were calculated with 95% confidence intervals. Publication bias and sensitivity analyses were also performed using STATA 14.0.
Results
In total, 7 studies and 552 patients were included in the meta-analysis. Serum concentrations of endoxifen were significantly different in each
CYP2D6
*
10
genotype group (
p
< 0.05). The CC genotype was associated with higher concentrations of 4-OH-TAM than the CT/TT genotype (
p
< 0.05). However, there were no statistically significant between-group differences in serum concentrations of TAM (
p
> 0.05). Publication bias and sensitivity analyses confirmed that the meta-analysis results were stable and reliable.
Conclusions
CYP2D6
*
10
polymorphisms influence the pharmacokinetics of tamoxifen in patients with breast cancer in Asia.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30357449</pmid><doi>10.1007/s00280-018-3703-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2019-01, Vol.83 (1), p.71-79 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_2124646215 |
| source | SpringerLink Journals |
| subjects | Bias Biopsy Breast cancer Cancer Cancer Research Confidence intervals Correlation analysis CYP2D6 protein Cytochrome Cytochrome P450 Cytochromes P450 Gene polymorphism Genotype & phenotype Medicine Medicine & Public Health Meta-analysis Metabolites Oncology Original Article Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Polymorphism Sensitivity Sensitivity analysis Statistical analysis Tamoxifen |
| title | Effects of CYP2D610 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A53%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20CYP2D610%20polymorphism%20on%20tamoxifen%20pharmacokinetics%20in%20patients%20with%20breast%20cancer%20in%20Asia:%20a%20meta-analysis&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Bai,%20Yu&rft.date=2019-01-01&rft.volume=83&rft.issue=1&rft.spage=71&rft.epage=79&rft.pages=71-79&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-018-3703-8&rft_dat=%3Cproquest_cross%3E2124646215%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2124646215&rft_id=info:pmid/30357449&rfr_iscdi=true |